Parkinson's drugs may lead to compulsive behavior

November 2011
Mayo Clinic Health Letter;Nov2011, Vol. 29 Issue 11, p4
The article offers information on research which dealt with the association of some drugs for Parkinson's disease with the development of impulse control problems like hypersexuality and compulsive gambling.


Related Articles

  • Emerging Therapies in the Pharmacological Treatment of Parkinson’s Disease. Korczyn, A.D.; Nussbaum, M. // Drugs;2002, Vol. 62 Issue 5, p775 

    The pharmacological management of Parkinson’s disease is a complex and dynamic task; there is no one ‘right’ strategy indicating which drugs should be used at a particular stage of the disease. There are now many different drugs belonging to several classes that may be...

  • Ropinirole Prolonged Release.  // CNS Drugs;2009, Vol. 23 Issue 1, p81 

    â–² Ropinirole prolonged release is a non-ergoline dopamine receptor agonist that is indicated for the treatment of Parkinson's disease. â–² Once-daily ropinirole prolonged release and three-times-daily ropinirole immediate release have similar exposure over 24 hours. The...

  • Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson's disease. Ji Young Yun; Han-Joon Kim; Jee-Young Lee; Young Eun Kim; Ji Seon Kim; Jong-Min Kim; Beom S Jeon // BMC Neurology;2013, Vol. 13 Issue 1, p1 

    Background: Ropinirole prolonged release (RPR) is a once-daily formulation. However, there may be individual pharmacokinetic differences so that multiple dosing may be preferred in some individuals. This study compares once-daily and twice-daily RPR in patients with Parkinson's disease. Methods:...

  • Parkinson's disease.  // Age & Ageing;May2013 Supplement, Vol. 42 Issue suppl_2, pii28 

    The article presents an abstract on the topic of Parkinson's disease (PD) which includes the comparison of patient-rated treatment response with measured improvement in PD.

  • Fighting back. Cohen, Philip // New Scientist;07/31/99, Vol. 163 Issue 2197, p12 

    Focuses on ropinirole, a dopamine agonist which controls Parkinson's disease, and compares its effectiveness with that of L-dopa, the standard drug. The death of cells producing dopamine as the cause of Parkinson's disease, and symptoms which relate to loss of neurotransmitter activity, such as...

  • Jeu pathologique chez les patients atteints de la maladie de Parkinson. Nadeau, Dominic; Giroux, Isabelle; Dufour, Julie; Simard, Martine // Sante Mentale au Quebec;Printemps2012, Vol. 37 Issue 1, preceding p189 

    Pathological gambling implies an inadequate, persistent and chronic practice of gambling which has major impact on affected individuals, their families and the society (APA, 2003). Many risk factors of social, psychological and biological nature contribute to the development of pathological...

  • Rotigotine transdermal patch: a guide to its use in Parkinson's disease and restless leg syndrome. Lyseng-Williamson, Katherine; Sanford, Mark; Scott, Lesley // Drugs & Therapy Perspectives;Mar2013, Vol. 29 Issue 3, p57 

    Once-daily administration of the rotigotine transdermal patch (Neupro) is effective in treating patients with early Parkinson's disease (as monotherapy), advanced Parkinson's disease (in combination with levodopa), inadequate morning motor control despite antiparkinsonian treatment (mostly in...

  • Evidence-based initiation of dopaminergic therapy in Parkinson's disease. Miyasaki, Janis M. // Journal of Neurology;Nov2010, Vol. 257, p309 

    The mainstay of Parkinson's disease (PD) therapy is levodopa. The crucial question is when should levodopa be initiated? Levodopa provides the most potent motor benefit for PD, but longer term use is marked by the development of motor complications such as fluctuations in response and...

  • Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease. Hauser, Robert A. // Evidence Based Medicine;Feb2015, Vol. 20 Issue 1, p17 

    The author comments on an article related to long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors as compared with levodopa drug for the treatment of Parkinson's disease (PD) by R. Gray and others, appeared in the 2014 issue of periodical "Lancet." Topics include use...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics